Enterprise Value
47.1M
Cash
205.4M
Avg Qtr Burn
-57.74M
Short % of Float
12.00%
Insider Ownership
14.40%
Institutional Own.
62.64%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Giroctocogene fitelparvovec (SB-525 / PF-07055480) Details Rare diseases, Hemophilia, Rare genetic disease, Blood disorder | Phase 3 Data readout | |
TX-200 Details Kidney disease, Kidney transplantation | Phase 1/2 Interim update | |
ST-920 (isaralgagene civaparvovec) Details Fabry disease, Rare genetic disease | Phase 1/2 Update | |
BIVV003 (SAR445136) Details Sickle cell disease, Blood disorder | Failed Discontinued | |
ST-400 Details Blood disorder, Beta thalessemia | Failed Discontinued | |
SB-913 Details Genetic disorder, Rare diseases, Mucopolysaccharidoses, Rare genetic disease, Mucopolysaccharidosis type II | Failed Discontinued |